Last SFr.284.00 CHF
Change Today +2.75 / 0.98%
Volume 35.3K
RO On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 11:43 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RO) Snapshot

Open
SFr.282.00
Previous Close
SFr.281.25
Day High
SFr.284.00
Day Low
SFr.281.50
52 Week High
11/21/14 - SFr.284.00
52 Week Low
12/16/13 - SFr.229.70
Market Cap
249.1B
Average Volume 10 Days
38.2K
EPS TTM
SFr.12.68
Shares Outstanding
160.0M
EX-Date
03/6/14
P/E TM
22.4x
Dividend
SFr.7.80
Dividend Yield
2.75%
Current Stock Chart for ROCHE HOLDING AG-BR (RO)

roche holding ag-br (RO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-br (RO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-br (RO) Key Developments

Roche Teams Up with LabCentral to Support Biotech Startups

LabCentral and Roche announced an agreement in which Roche would provide technology and financial support to LabCentral, a shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. Roche instruments will expand capacity for LabCentral resident companies performing high-throughput DNA studies. They include a MagNA Pure 96 robotic workstation for automated purification of nucleic acids, LightCycler(R) 96 Real-Time PCR system, and automated reagent freezer.

Roche Holding AG Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 01:30 PM

Roche Holding AG Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 01:30 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Bob Silverman.

Roche Holding AG Presents at UBS European Conference 2014, Nov-12-2014 10:30 AM

Roche Holding AG Presents at UBS European Conference 2014, Nov-12-2014 10:30 AM. Venue: London, United Kingdom. Speakers: Karl Mahler, Head of Investor Relations, Stefan Frings, Medical Affairs Director Roche Germany.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RO:SW SFr.284.00 CHF +2.75

RO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €117.17 EUR +3.34
General Electric Co $26.99 USD +0.14
Gilead Sciences Inc $100.58 USD -0.01
Merck & Co Inc $59.66 USD +0.28
Novartis AG SFr.91.95 CHF +0.45
View Industry Companies
 

Industry Analysis

RO

Industry Average

Valuation RO Industry Range
Price/Earnings 21.3x
Price/Sales 4.6x
Price/Book 12.9x
Price/Cash Flow 17.3x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.